Investor disappointment as vaccines again come up short, despite the Q3 beat
30/10/24 -"Even the better-than-expected Q3 results failed to impress investors, as GSK’s key vaccines fell short of the street’s estimates, causing worries for future growth. Nonetheless, other areas ..."
Pages
73
Language
English
Published on
30/10/24
You may also be interested by these reports :
12/06/25
Only a month ago we were lamenting the weakness of Pharmas, the second larget sector by market cap. The tide may have turned, strangely as part ...
11/06/25
Faes Farma made a good move to acquire the Italian ophthalmology firm SIFI, whose enterprise value is c.20% of Faes’ market cap. This deal would not ...
11/06/25
A sector review of ytd performance would show that the money was on Aerospace Defence and Financials. Pain was to be experienced with Consumer ...
10/06/25
A pest threatens the 2025 potato harvest with failure rates of up to 70%. We believe the driest spring on record has contributed to this. In the ...